Ocumont (Chloramphenicol)

Chloramphenicol, the active ingredient in Ocumont, is a broad‑spectrum antibiotic presented as a topical ophthalmic solution for ocular use. It treats bacterial eye infections such as conjunctivitis and keratitis in adults and children.

GNH USA supplies Ocumont as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Chloramphenicol is a bacteriostatic agent used in ophthalmology to manage infections caused by susceptible organisms. - Bacterial conjunctivitis: reduces inflammation and clears infection caused by common ocular pathogens. - Keratitis: helps eradicate bacterial invasion of the cornea, supporting visual recovery. - Post‑surgical prophylaxis: prevents bacterial contamination after eye surgery, reducing infection risk.

Adverse reactions to chloramphenicol ophthalmic preparations are generally mild but can vary in severity.

Common Side Effects: - Burning or stinging sensation upon instillation. - Temporary blurred vision. - Mild ocular irritation or redness. - Foreign‑body sensation.

Serious or Rare Side Effects: - Allergic contact dermatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bone marrow suppression leading to aplastic anemia (systemic absorption risk). - Severe ocular inflammation or ulceration.

Chloramphenicol ophthalmic solution should be used with caution and according to professional guidance. - Contraindication: Known hypersensitivity to chloramphenicol or any component of the formulation. - Pregnancy: Use only if clearly needed; systemic absorption may pose fetal risk. - Breastfeeding: Avoid unless benefits outweigh potential risks to the infant. - Monitoring: Observe for signs of systemic toxicity, especially with prolonged use. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Chloramphenicol may interact with other medications, altering efficacy or safety.

Major Interactions (Avoid): - Systemic aminoglycosides: increased risk of ototoxicity when systemic absorption occurs. - Warfarin: potential enhancement of anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase local irritation. - Other topical antibiotics: additive toxicity to ocular surface. - Systemic corticosteroids: may mask signs of infection, delaying detection.